Catalyst Biosciences Inc (NASDAQ:CBIO) – B. Riley issued their FY2022 EPS estimates for shares of Catalyst Biosciences in a report released on Monday. B. Riley analyst G. Zavoico forecasts that the biopharmaceutical company will post earnings per share of $2.70 for the year. B. Riley has a “Buy” rating and a $49.00 price objective on the stock.
Several other research analysts also recently weighed in on CBIO. ValuEngine upgraded shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, January 1st. Finally, Chardan Capital upped their target price on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $37.50.
A number of hedge funds and other institutional investors have recently bought and sold shares of CBIO. Dimensional Fund Advisors LP boosted its stake in Catalyst Biosciences by 117.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 173,555 shares of the biopharmaceutical company’s stock valued at $873,000 after acquiring an additional 93,592 shares during the last quarter. Vanguard Group Inc. boosted its stake in Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after acquiring an additional 32,621 shares during the last quarter. Geode Capital Management LLC bought a new position in Catalyst Biosciences during the 4th quarter valued at $379,000. Bank of New York Mellon Corp bought a new position in Catalyst Biosciences during the 2nd quarter valued at $107,000. Finally, Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences during the 2nd quarter valued at $103,000. Hedge funds and other institutional investors own 22.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/13/catalyst-biosciences-inc-expected-to-earn-fy2022-earnings-of-2-70-per-share-cbio.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.